Abstract
Uterine leiomyomas (ULs) are the most common benign tumor, affecting approximately 70-80% of women in their reproductive age, and can cause heavy bleeding, pain, and infertility. Recent evidence suggests that simvastatin may have anti-leiomyoma properties. Leiomyoma arises from the transformation of myometrial stem cells into tumor-initiating cells that undergo self-renewal and differentiation to mature cells, necessary for tumor growth. Wnt/β-catenin pathways are overexpressed in UL, involved in stem cell self-renewal, cross-talk between stem and mature cells, cellular proliferation, extracellular matrix (ECM) accumulation and drive UL growth.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
